Pandemic Influenza Vaccine Policy -- Considering the Early Evidence
This editorial, published in The New England Journal of Medicine (NEJM), comments on two articles released through NEJM (Greenberg et al. and Clark et al.) that describe preliminary data on the immunogenicity of the influenza A (H1N1) 2009 monovalent vaccine. The author discusses the implications of the data that shows a single dose of nonadjuvanted vaccine as immunogenetic in healthy young and middle-aged adults. She acknowledges the advantages of this preliminary data for reasons of dose sparing and more rapid immune responses, but also notes that more data is needed to make conclusions about immunogenicity in children or in adults with underlying immune suppression or high-risk conditions. The author also mentions that additional studies are ongoing to assess the immunogenicity of live, attenuated vaccines against the 2009 pandemic influenza A (H1N1). In sum, she emphasizes that a balance must be found between trying to see all the data and the need to deploy vaccine quickly to reduce morbidity.
Author(s): Neuzil KM
Visit web page (English)
(Located at content.nejm.org)
Citation: Neuzil KM. Pandemic Influenza Vaccine Policy -- Considering the Early Evidence. New England Journal of Medicine. 2009. Epub ahead of print.